0001448431 false 0001448431 2023-11-06 2023-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): November 6, 2023

 

OptimizeRx Corporation

(Exact name of registrant as specified in charter)

 

Nevada   001-38543   26-1265381
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

260 Charles Street, Suite 302, Waltham, MA   02453
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 248.651.6568

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 Par Value   OPRX   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 6, 2023, OptimizeRx Corporation issued a press release announcing its financial results for the third quarter ended September 30, 2023. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

 

The information in this Item 2.02 and Exhibit 99.1 attached hereto are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit
Number
  Description
99.1   Press Release, dated November 6, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  OPTIMIZERX CORPORATION
     
Date: November 6, 2023 By: /s/ Edward Stelmakh
  Name:  Edward Stelmakh
  Title: Chief Financial Officer

 

 

2

 

 

Exhibit 99.1

 


OptimizeRx Reports Third Quarter 2023 Financial Results

 

- Increases guidance for 2023 and introduces guidance for 2024

 

- Total revenue of $16.3 million

- GAAP net loss per share of $(0.17)

- Non-GAAP net income per share of $0.09

- Total DAAP (fka RWD) deals for the year now stands at 16

- Completed acquisition of Medicx Health after quarter end

 

WALTHAM, Mass. – November 6, 2023 – OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended September 30, 2023. Quarterly comparisons are to the same year-ago period.

 

Financial Highlights

 

Revenue in the third quarter of 2023 increased 8% to $16.3 million, as compared to $15.1 million in the same year ago period.

 

Gross profit in the third quarter of 2023 increased 4% year-over-year to $9.8 million, from $9.4 million during the third quarter of 2022.

 

GAAP net loss totaled $(2.9) million or $(0.17) per basic and diluted shares outstanding in the third quarter, as compared to $(3.5) million or $(0.19) during the third quarter of 2022.

 

Non-GAAP net income in the third quarter totaled $1.6 million or $0.09 per fully diluted shares outstanding, as compared to $1.3 million or $0.07 per fully diluted shares outstanding during the third quarter of 2022 (see definition of this non-GAAP measure and reconciliation to GAAP, below).

 

Adjusted EBITDA for the third quarter of 2023 came in at $0.9 million compared to $1.0 million in the same year ago period (see definition of this non-GAAP measure and reconciliation to GAAP, below).

 

Cash, cash equivalents and short-term investments totaled $63.5 million as of September 30, 2023 as compared to $74.1 million as of December 31, 2022

 

Will Febbo, OptimizeRx CEO commented, “I am excited to announce third quarter results came in well above expectations. We’ve seen significant momentum build up since the start of the second half of 2023, particularly around the utilization of our Dynamic Audience Activation Platform (DAAP). In fact, our total number of deals for the year is tracking ahead of expectations and now stands at 16. The macro headwinds we’ve been highlighting since the middle of last year have seemed to normalize and large pharma that started initial pilot programs with companies that had newly entered the space are now completing the measurement of these programs and, as we expected, have learned that these solutions are not scalable and are beginning to drive spend back our way.”

 

“As a result, we couldn’t have asked for better timing to complete the acquisition of Medicx Health. Both business lines are showing growth, profitability, and are seeing significant client engagement. We are also moving forward as planned on executing against the numerous revenue, technological and operational synergies we identified. On a combined basis, revenues are expected to quickly surpass $100 million over the next 12 months while generating profitability and cash flow. The transaction further expands our omnichannel reach beyond HCPs to patients while adding multiple channels we haven’t accessed previously. The ability to provide significant scale for pharma manufacturers is quickly moving us up the decision maker hierarchy within our larger customers.”

 

 

 

 

“Given that backdrop, I’m happy to say, we’re increasing our guidance for 2023 and are now looking for revenue and adjusted EBITDA to come in between $68-$70 million and $3-$4 million, respectively, for the year. We expect OptimizeRx’s pre-acquisition business will account for $63 to $65 million of 2023’s revenue guidance, which is up from our previous guidance which called for revenue to be in the mid-50 to low-60 million dollar range. We’re also introducing preliminary 2024 guidance and expect revenue to be at least $110 million and expect adjusted EBITDA margins to be at least 10%.”

 

Key Performance Indicators (KPIs)*   Rolling
Twelve Months
Ended
September 30,

2023
    Rolling
Twelve Months
Ended
June 30,
2023
 
Average revenue per top 20 pharmaceutical manufacturer   $ 2,075,078     $ 1,972,308  
Percent of top 20 pharmaceutical manufacturers that are customers     90 %     90 %
Top 20 pharmaceutical manufacturers as percent of total net revenues     59 %     58 %
Net revenue retention     93 %     89 %
Revenue per averages full-time employee (FTE)   $ 570,973     $ 559,646  

 

2023 Financial Outlook

 

Based on OptimizeRx’s results for the first nine months of 2023 and its recent acquisition, the Company is updating its full year financial outlook for 2023. Revenues for 2023 are now expected to be between $68 million and $70 million and we expect our adjusted EBITDA to come in between $3 million and $4 million.

 

The Company is introducing preliminary 2024 guidance at this time and expects revenue to be at least $110 million with an adjusted EBITDA margin of at least 10%.

 

Conference Call

 

Date: Monday, November 6, 2023  
Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)  
Toll Free: 1-877-423-9813
International: 1-201-689-8573
Conference ID: 13742267

Call Me Link: https://callme.viavid.com/viavid/?callme=true&passcode=13742267&h=true&info=company-email&r=true&B=6

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1640427&tp_key=4d243008bb.

 

2

 

 

Definition and Use of Non-GAAP Financial Measures

 

This earnings release includes a presentation of non-GAAP net income (loss) and non-GAAP net income (loss) per diluted share or non-GAAP EPS, Adjusted EBITDA and Adjusted EBITDA margin, all of which are non-GAAP financial measures.

 

The Company defines non-GAAP net income (loss) as GAAP net income (loss) with an adjustment to add back depreciation, amortization, stock-based compensation, acquisition expenses, severance expense related to a reduction in force, income or loss related to the fair value of contingent consideration, and deferred income taxes. Non-GAAP EPS is defined as non-GAAP net income (loss) divided by the number of weighted average shares outstanding on a diluted basis. Adjusted EBITDA is defined as GAAP net income (loss) with an adjustment to add back depreciation, amortization, interest, stock-based compensation, acquisition expenses, severance expense related to a reduction in force, income or loss related to the fair value of contingent consideration, and deferred income taxes. Adjusted EBITDA margin is defined as Adjusted EBITDA divided by revenue. The Company has provided non-GAAP financial measures to aid investors in better understanding its performance. Management believes that these non-GAAP financial measures provide additional insight into the operations and cash flow of the Company.

 

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a Company’s non-cash operating expenses, management believes that providing non-GAAP financial measures that exclude non-cash expenses allows for meaningful comparisons between the Company’s core business operating results and those of other companies, as well as provides an important tool for financial and operational decision making and for evaluating the Company’s own core business operating results over different periods of time.

 

The Company’s non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company’s industry, as other companies in the industry may calculate such non-GAAP financial results differently. The Company’s non-GAAP net income (loss), non-GAAP EPS, Adjusted EBITDA and Adjusted EBITDA margin are not measurements of financial performance under GAAP and should not be considered as an alternative to operating income or as an indication of operating performance or any other measure of performance derived in accordance with GAAP. The Company does not consider these non-GAAP measures to be substitutes for or superior to the information provided by its GAAP financial results.

 

The table, “Reconciliation of GAAP to NON-GAAP Financial Measures,” included below, provides a reconciliation of non-GAAP net income (loss), non-GAAP EPS, and Adjusted EBITDA for the three and nine months ended September 30, 2023 and 2022. Although the Company provides guidance for Adjusted EBITDA and Adjusted EBITDA margin, it is not able to provide guidance to the most directly comparable GAAP measures. Reconciliations for forward-looking figures would require unreasonable efforts at this time because of the uncertainty and variability of the nature and amount of certain components of various necessary GAAP components, including, for example, those related to compensation, acquisition expenses, amortization or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision that would be confusing or misleading to investors. For the same reasons, the Company is unable to address the probable significance of the unavailable information.

 

3

 

 

Definition of Key Performance Indicators*

 

Top 20 pharmaceutical manufacturers: The definition of “top 20 pharmaceutical manufacturers” is based upon Fierce Pharma’s list of “The top 20 pharma companies by 2022 revenue”.

 

Net revenue retention: Net revenue retention is a comparison of revenue generated from all clients in the previous period to total revenue generated from the same clients in the following year (i.e., excludes new client relationships for the most recent year).

 

Revenue per average Full Time Employee: We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM, which is calculated by taking our total number of FTEs at the end of the prior year period by our total FTE headcount at the end of the most recent.

 

About OptimizeRx

 

OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through the most intelligent technology platform embedded within a proprietary digital point-of-care network, OptimizeRx helps patients start and stay on their medications. 

 

For more information, follow the Company on Twitter, LinkedIn or visit www.optimizerx.com. 

 

Important Cautions Regarding Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans, future performance, expected revenues, expected Adjusted EBITDA, expected adjusted EBITDA margin and prospects. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, any synergies and other anticipated benefits of the Medicx merger may not be realized or may take longer than anticipated to be realized; the risk that the integration of OptimizeRx and Medicx will be more costly or difficult than expected; the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.

 

OptimizeRx Contact

 

Andy D’Silva, SVP Corporate Finance

adsilva@optimizerx.com

 

Investor Relations Contact

 

Ashley Robinson

LifeSci Advisors, LLC

arr@lifesciadvisors.com

 

4

 

 

OPTIMIZERX CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

   September 30,
2023
   December 31,
2022
 
         
ASSETS        
Current assets        
Cash and cash equivalents  $9,921,475   $18,208,685 
Short-term investments   53,620,576    55,931,821 
Accounts receivable, net   20,838,762    22,155,301 
Prepaid expenses and other   3,008,858    2,280,828 
Total current assets   87,389,671    98,576,635 
Property and equipment, net   149,304    137,448 
Other assets          
Goodwill   22,673,820    22,673,820 
Technology assets, net   7,548,337    7,702,895 
Patent rights, net   1,777,669    1,940,178 
Deferred financing costs   300,000     
Right of use assets, net   148,641    235,320 
Other intangible assets, net   3,141,709    3,384,889 
Other long-term assets   800,000     
Total other assets   36,390,176    35,937,102 
TOTAL ASSETS  $123,929,152   $134,651,185 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable – trade   691,159    1,549,979 
Accrued expenses   3,108,907    2,601,246 
Revenue share payable   3,685,390    3,990,440 
Current portion of lease liabilities   27,687    89,902 
Deferred revenue   188,394    164,309 
Total current liabilities   7,701,538    8,395,876 
Non-current liabilities          
Lease liabilities, net of current portion   120,955    144,532 
Total liabilities   7,822,493    8,540,408 
           
Stockholders’ equity          
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding at September 30, 2023 or December 31, 2022        
Common stock, $0.001 par value, 166,666,667 shares authorized, 18,386,920 and 18,288,571 shares issued at September 30, 2023 and December 31, 2022, respectively   18,387    18,289 
Treasury stock, $0.001 par value, 1,741,397 and 1,214,398 shares held at September 30, 2023 and December 31, 2022, respectively   (1,741)   (1,214)
Additional paid-in-capital   176,206,572    172,785,800 
Accumulated deficit   (60,116,559)   (46,692,098)
Total stockholders’ equity  $116,106,659   $126,110,777 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $123,929,152   $134,651,185 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5

 

 

OPTIMIZERX CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   For the Three Months
Ended
September 30,
   For the Nine Months
Ended
September 30,
 
   2023   2022   2023   2022 
                 
Net revenue  $16,331,484   $15,085,504   $43,152,560   $42,795,699 
Cost of revenues, exclusive of depreciation and amortization presented separately below   6,531,183    5,664,733    18,093,949    16,283,307 
Gross profit   9,800,301    9,420,771    25,058,611    26,512,392 
                     
Operating expenses                    
General and administrative expenses   12,887,083    12,661,703    39,161,752    36,373,298 
Depreciation, amortization and noncash lease expense   466,706    515,828    1,395,400    1,565,484 
Total operating expenses   13,353,789    13,177,530    40,557,152    37,938,782 
Loss from operations   (3,553,487)   (3,756,759)   (15,498,541)   (11,426,390)
Other income                    
Interest income   688,190    289,967    2,074,081    313,786 
Loss before provision for income taxes   (2,865,297)   (3,466,792)   (13,424,460)   (11,112,604)
Income tax benefit                
Net loss  $(2,865,297)  $(3,466,792)  $(13,424,460)  $(11,112,604)
Weighted average number of shares outstanding – basic   16,637,606    17,981,184    16,907,482    17,994,288 
Weighted average number of shares outstanding – diluted   16,637,606    17,981,184    16,907,482    17,994,288 
Loss per share – basic  $(0.17)  $(0.19)  $(0.79)  $(0.62)
Loss per share – diluted  $(0.17)  $(0.19)  $(0.79)  $(0.62)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6

 

 

OPTIMIZERX CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

   For the Nine Months
Ended
September 30,
 
   2023   2022 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss  $(13,424,460)  $(11,112,604)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:          
Depreciation and amortization   1,395,400    1,565,484 
Stock-based compensation   11,089,853    11,476,662 
Increase in bad debt reserve   478,086    132,727 
Changes in:          
Accounts receivable   838,453    6,854,150 
Prepaid expenses and other assets   (728,030)   2,199,333 
Accounts payable   (858,820)   393,817 
Revenue share payable   (305,049)   (1,704,593)
Accrued expenses and other liabilities   508,548    (1,237,689)
Deferred revenue   24,084    (716,693)
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES   (981,935)   7,850,594 
           
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:          
Purchase of property and equipment   (81,767)   (64,667)
Purchases of held-to-maturity investments   (162,777,510)   (37,468,889)
Redemptions of held-to-maturity investments   165,088,755     
EvinceMed acquisition       (2,000,000)
Acquisition of intangible assets, including intellectual property rights   (3,796)   (158,321)
Capitalized software development costs   (1,561,447)    
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES   664,235    (39,691,877)
           
CASH FLOWS (USED IN) PROVIDED BY FINANCING ACTIVITIES:          
Cash paid for employee withholding taxes related to the vesting of restricted stock units   (292,789)    
Repurchase of common stock   (7,522,426)   (12,561,571)
Proceeds from exercise of stock options   145,706    1,050,104 
Loan origination costs   (300,000)    
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES   (7,969,509)   (11,511,467)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS   (8,287,209)   (43,352,750)
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD   18,208,685    84,681,770 
CASH AND CASH EQUIVALENTS - END OF PERIOD  $9,921,475   $41,329,020 
           
SUPPLEMENTAL CASH FLOW INFORMATION:          
Cash paid for interest  $   $ 
Reduction of EvinceMed purchase price for amounts previously paid  $   $708,334 
Shares issued in connection with acquisition  $   $9,374,455 
Cash paid for income taxes  $   $ 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

7

 

 

OPTIMIZERX CORPORATION

RECONCILIATION of GAAP to NON-GAAP FINANCIAL MEASURES

(UNAUDITED)

 

   Three Months Ended
September 30, 2023
   Nine months ended
September 30, 2023
 
   2023   2022   2023   2022 
Net loss  $(2,865,297)  $(3,466,792)  $(13,424,460)  $(11,112,604)
Depreciation, amortization and noncash lease expense   466,706    515,828    1,395,400    1,565,484 
Stock-based compensation   3,206,227    4,277,241    11,089,853    11,476,662 
Severance expense   206,477        206,477     
Acquisition expense   554,741        580,691    22,318 
Non-GAAP net income (loss)   1,568,854    1,326,277    (152,039)   1,951,860 
                     
Non-GAAP net income (loss) per share                    
Diluted  $0.09   $0.07   $(0.01)  $0.11 
Weighted average shares outstanding:                    
Diluted   16,648,778    18,088,406    16,907,482    18,011,885 

 

   Three Months Ended
September 30, 2023
   Nine months ended
September 30, 2023
 
   2023   2022   2023   2022 
Net loss  $(2,865,297)  $(3,466,792)  $(13,424,460)  $(11,112,604)
Depreciation, amortization and noncash lease expense   466,706    515,828    1,395,400    1,565,484 
Stock-based compensation   3,206,227    4,277,241    11,089,853    11,476,662 
Severance expense   206,477        206,477     
Acquisition expense   554,741        580,691    22,318 
Interest income   (688,190)   (289,967)   (2,074,081)   (313,786)
Adjusted EBITDA   880,664    1,036,310    (2,226,120)   1,638,074 

 

 

8

 

v3.23.3
Cover
Nov. 06, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 06, 2023
Entity File Number 001-38543
Entity Registrant Name OptimizeRx Corporation
Entity Central Index Key 0001448431
Entity Tax Identification Number 26-1265381
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 260 Charles Street
Entity Address, Address Line Two Suite 302
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02453
City Area Code 248
Local Phone Number 651.6568
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 Par Value
Trading Symbol OPRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Jan 2024 to Feb 2024 Click Here for more OptimizeRx Charts.
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Feb 2023 to Feb 2024 Click Here for more OptimizeRx Charts.